A Multiple Dose, Placebo-Controlled, Randomized Study of ALD403, a Humanized Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody, Administered Once Every 3-Months Intravenously, Subcutaneously, or Intramuscularly

Baker B. B.; Smith J. T.; Schaeffler B. A.

首页> 外文期刊>Headache >A Multiple Dose, Placebo-Controlled, Randomized Study of ALD403, a Humanized Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody, Administered Once Every 3-Months Intravenously, Subcutaneously, or Intramuscularly

【24h】

A Multiple Dose, Placebo-Controlled, Randomized Study of ALD403, a Humanized Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody, Administered Once Every 3-Months Intravenously, Subcutaneously, or Intramuscularly

机译：人源化抗降钙素基因相关肽单克隆抗体ALD403的多剂量，安慰剂对照，随机研究，每3个月一次，静脉内，皮下或肌肉内给药

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Headache》 |2016年第8期|共1页
作者
Baker B. B.; Smith J. T.; Schaeffler B. A.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类诊断学;
关键词

相似文献

外文文献
中文文献
专利

1. A Multiple Dose, Placebo-Controlled, Randomized Study of ALD403, a Humanized Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody, Administered Once Every 3-Months Intravenously, Subcutaneously, or Intramuscularly [J] . Baker B. B., Smith J. T., Schaeffler B. A. Headache . 2016,第8期

机译：人源化抗降钙素基因相关肽单克隆抗体ALD403的多剂量，安慰剂对照，随机研究，每3个月一次，静脉内，皮下或肌肉内给药
2. Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab [J] . Robert Bissonnette, Richard G. Langley, Kim Papp, Archives of Dermatological Research . 2009,第6期

机译：人源化抗CD2单克隆抗体治疗斑块状牛皮癣：两项随机，双盲，安慰剂对照的静脉和皮下siplizumab研究的疗效和药效学结果
3. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study [J] . Mark A Agius, Gabriela Klodowska-Duda, Maciej Maciejowski, Multiple sclerosis: clinical and laboratory research . 2019,第2期

机译：inebilizumab（Medi-551），一种抗CD19单克隆抗体，复杂的多发性硬化形式的抗CD19单克隆抗体的安全性：由A相随机，安慰剂控制，静脉内和皮下剂量研究的结果
4. Safety and tolerability of inebilizumab (MEDI-551) an anti-CD19 monoclonal antibody in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised placebo-controlled escalating intravenous and subcutaneous dose study [O] . Mark A Agius, Gabriela Klodowska-Duda, Maciej Maciejowski, -1

机译：复发性多发性硬化患者中抗CD19单克隆抗体inebilizumab（MEDI-551）的安全性和耐受性：随机安慰剂对照逐步增加的静脉和皮下剂量研究的1期结果
5. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. [O] . Kenneth H Mayer, Kelly E Seaton, Yunda Huang, 2017

机译：多种静脉内或皮下剂量的抗HIV单克隆抗体VRC01的安全性，药代动力学和免疫活性，给予HIV未感染的成人：1期随机试验的结果。

A Multiple Dose, Placebo-Controlled, Randomized Study of ALD403, a Humanized Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody, Administered Once Every 3-Months Intravenously, Subcutaneously, or Intramuscularly

著录项

相似文献

相关主题

期刊订阅